Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 16/20 | 0.95 |
| ▸ | GABRB2 | P47870 | 16/20 | 0.95 |
| ▸ | GABRP | O00591 | 6/20 | 0.95 |
| ▸ | GABRD | O14764 | 6/20 | 0.95 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.95 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.95 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.95 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.95 |
| ▸ | GABRA3 | P34903 | 6/20 | 0.95 |
| ▸ | GABRA2 | P47869 | 6/20 | 0.95 |
| ▸ | GABRA4 | P48169 | 6/20 | 0.95 |
| ▸ | GABRE | P78334 | 6/20 | 0.95 |
| ▸ | GABRA6 | Q16445 | 6/20 | 0.95 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.95 |
| ▸ | GABRG3 | Q99928 | 6/20 | 0.95 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28620629 | 0.90 | GABRA1 (0.85) | GABRA1GABRB2GABRPGABRDGABRB1 | |
| SCHEMBL26665197 | 0.86 | GABRA1 (1.00) | GABRA1GABRB2GABRPGABRDGABRB1 | |
| Gabazine SCHEMBL16320027 | 0.82 | GABRA1 (0.95) | GABRA1GABRB2GABRPGABRDGABRB1 | |
| Gabazine SCHEMBL5529434 | 0.81 | GABRA1 (1.00) | GABRA1GABRB2GABRPGABRDGABRB1 | |
| SCHEMBL2739432 | 0.81 | GABRA1 (0.90) | GABRA1GABRB2GABRPGABRDGABRB1 | |
| Gabazine SCHEMBL5473649 | 0.81 | GABRA1 (0.98) | GABRA1GABRB2GABRPGABRDGABRB1 | |
| SCHEMBL28623937 | 0.78 | GABRA1 (0.80) | GABRA1GABRB2GABRPGABRDGABRB1 | |
| SCHEMBL28628919 | 0.77 | GABRA1 (0.84) | GABRA1GABRB2GABRPGABRDGABRB1 | |
| SCHEMBL28620573 | 0.76 | GABRA1 (0.66) | GABRA1GABRB2GABRPGABRDGABRB1 | |
| SCHEMBL28634719 | 0.76 | GABRA1 (0.66) | GABRA1GABRB2GABRPGABRDGABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200085790-A1 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2020-03-19 | — | — | US | disclosed |
| US-20170231958-A1 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROLOGICAL DISORDERS | PHARNEXT S.A. (FR) | 2017-08-17 | — | — | US | disclosed |
| US-9636316-B2 | Baclofen and acamprosate based therapy of neurological disorders | PHARNEXT (FR) | 2017-05-02 | — | — | US | disclosed |
| US-20160000736-A1 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROLOGICAL DISORDERS | PHARNEXT S.A. (FR) | 2016-01-07 | — | — | US | disclosed |
| US-9144558-B2 | Baclofen and acamprosate based therapy of neurological disorders | PHARNEXT (FR) | 2015-09-29 | — | — | US | disclosed |
| US-20140378440-A1 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROLOGICAL DISORDERS | PHARNEXT S.A. (FR) | 2014-12-25 | — | — | US | disclosed |